- Home
- ETWO vs ETNB Comparison
ETWO vs ETNB Comparison
Compare ETWO & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETWO
- ETNB
- Stock Information
- Founded
- ETWO 2000
- ETNB 2018
- Country
- ETWO United States
- ETNB United States
- Employees
- ETWO N/A
- ETNB N/A
- Industry
- ETWO EDP Services
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- ETWO Technology
- ETNB Health Care
- Exchange
- ETWO Nasdaq
- ETNB Nasdaq
- Market Cap
- ETWO 936.3M
- ETNB 867.4M
- IPO Year
- ETWO N/A
- ETNB 2019
- Fundamental
- Price
- ETWO $3.03
- ETNB $8.76
- Analyst Decision
- ETWO Hold
- ETNB Buy
- Analyst Count
- ETWO 3
- ETNB 7
- Target Price
- ETWO $3.90
- ETNB $30.33
- AVG Volume (30 Days)
- ETWO 1.7M
- ETNB 1.0M
- Earning Date
- ETWO 01-07-2025
- ETNB 11-07-2024
- Dividend Yield
- ETWO N/A
- ETNB N/A
- EPS Growth
- ETWO N/A
- ETNB N/A
- EPS
- ETWO N/A
- ETNB N/A
- Revenue
- ETWO $619,301,000.00
- ETNB N/A
- Revenue This Year
- ETWO N/A
- ETNB N/A
- Revenue Next Year
- ETWO $3.01
- ETNB $133.30
- P/E Ratio
- ETWO N/A
- ETNB N/A
- Revenue Growth
- ETWO N/A
- ETNB N/A
- 52 Week Low
- ETWO $2.89
- ETNB $7.00
- 52 Week High
- ETWO $5.08
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- ETWO 40.28
- ETNB 52.71
- Support Level
- ETWO $2.89
- ETNB $7.68
- Resistance Level
- ETWO $3.10
- ETNB $10.01
- Average True Range (ATR)
- ETWO 0.13
- ETNB 0.72
- MACD
- ETWO 0.01
- ETNB -0.12
- Stochastic Oscillator
- ETWO 24.11
- ETNB 35.63
About ETWO E2open Parent Holdings Inc.Class A
E2open Parent Holdings Inc is an end-to-end and cloud-based supply chain management SaaS platform. The company's software combines networks, data, and applications to provide a deeply embedded, mission-critical platform that allows customers to optimize the supply chain across channel shaping, business planning, logistics, trade, manufacturing, and supply management. The Group has one reportable segment consisting of cloud-based, end-to-end SCM software. Geographically, the company operates in the Americas, Europe, and Asia Pacific, out of which the majority is from the Americas.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).